Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis Fungoides
The morphologic changes in early-stage mycosis fungoides (MF) might overlap with benign inflammatory dermatitis (BID). Previous studies have described altered expression patterns of several proteins in MF, but their diagnostic significance is uncertain. This study aims at examining the frequency of...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/1/220 |
| _version_ | 1797494685186392064 |
|---|---|
| author | Tariq N. Aladily Tasnim Abushunar Ahmad Alhesa Raneen Alrawi Noor Almaani Maram Abdaljaleel |
| author_facet | Tariq N. Aladily Tasnim Abushunar Ahmad Alhesa Raneen Alrawi Noor Almaani Maram Abdaljaleel |
| author_sort | Tariq N. Aladily |
| collection | DOAJ |
| description | The morphologic changes in early-stage mycosis fungoides (MF) might overlap with benign inflammatory dermatitis (BID). Previous studies have described altered expression patterns of several proteins in MF, but their diagnostic significance is uncertain. This study aims at examining the frequency of expression of CD45RO, NFkB-p105/p50, JAK3, TOX, and IL-17 proteins by immunohistochemistry. The cohorts included 21 patients of early-stage MF and 19 with benign BID as a control group. CD45RO was positive in all patients of MF and BID. NFkB-p105/p50 showed normal cytoplasmic staining, indicating an inactive status in all patients of both groups. JAK3 was positive in 3 (14%) MF and in 17 (89%) BID patients (<i>p</i> = 0.003). TOX was expressed in 19 (90%) and 13 (68%) patients of MF and BID, respectively (<i>p</i> = 0.120). IL-17 was detected in 13 (62%) MF and in 7 (37%) BID patients (<i>p</i> = 0.056). Co-expression of TOX and IL-17 was seen in 11 (52%) MF patients but in only 3 (16%) BID patients, which was statistically significant (<i>p</i> = 0.021). We conclude that a double expression of TOX and IL-17 may support the diagnosis of MF in the right clinicopathologic setting, while none of the immunohistochemical stains alone provided a significant discrimination between MF and BID. |
| first_indexed | 2024-03-10T01:37:54Z |
| format | Article |
| id | doaj.art-e5a494892d7749be8c204e342a43a2da |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T01:37:54Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-e5a494892d7749be8c204e342a43a2da2023-11-23T13:30:19ZengMDPI AGDiagnostics2075-44182022-01-0112122010.3390/diagnostics12010220Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis FungoidesTariq N. Aladily0Tasnim Abushunar1Ahmad Alhesa2Raneen Alrawi3Noor Almaani4Maram Abdaljaleel5Department of Pathology, The University of Jordan, Amman 11942, JordanDepartment of Pathology, The University of Jordan, Amman 11942, JordanDepartment of Pathology, The University of Jordan, Amman 11942, JordanDepartment of Dermatology, The University of Jordan, Amman 11942, JordanDepartment of Dermatology, The University of Jordan, Amman 11942, JordanDepartment of Pathology, The University of Jordan, Amman 11942, JordanThe morphologic changes in early-stage mycosis fungoides (MF) might overlap with benign inflammatory dermatitis (BID). Previous studies have described altered expression patterns of several proteins in MF, but their diagnostic significance is uncertain. This study aims at examining the frequency of expression of CD45RO, NFkB-p105/p50, JAK3, TOX, and IL-17 proteins by immunohistochemistry. The cohorts included 21 patients of early-stage MF and 19 with benign BID as a control group. CD45RO was positive in all patients of MF and BID. NFkB-p105/p50 showed normal cytoplasmic staining, indicating an inactive status in all patients of both groups. JAK3 was positive in 3 (14%) MF and in 17 (89%) BID patients (<i>p</i> = 0.003). TOX was expressed in 19 (90%) and 13 (68%) patients of MF and BID, respectively (<i>p</i> = 0.120). IL-17 was detected in 13 (62%) MF and in 7 (37%) BID patients (<i>p</i> = 0.056). Co-expression of TOX and IL-17 was seen in 11 (52%) MF patients but in only 3 (16%) BID patients, which was statistically significant (<i>p</i> = 0.021). We conclude that a double expression of TOX and IL-17 may support the diagnosis of MF in the right clinicopathologic setting, while none of the immunohistochemical stains alone provided a significant discrimination between MF and BID.https://www.mdpi.com/2075-4418/12/1/220mycosis fungoidesCD45RONFkBp105/p50JAK3STAT3 |
| spellingShingle | Tariq N. Aladily Tasnim Abushunar Ahmad Alhesa Raneen Alrawi Noor Almaani Maram Abdaljaleel Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis Fungoides Diagnostics mycosis fungoides CD45RO NFkB p105/p50 JAK3 STAT3 |
| title | Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis Fungoides |
| title_full | Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis Fungoides |
| title_fullStr | Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis Fungoides |
| title_full_unstemmed | Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis Fungoides |
| title_short | Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis Fungoides |
| title_sort | immunohistochemical expression patterns of cd45ro p105 p50 jak3 tox and il 17 in early stage mycosis fungoides |
| topic | mycosis fungoides CD45RO NFkB p105/p50 JAK3 STAT3 |
| url | https://www.mdpi.com/2075-4418/12/1/220 |
| work_keys_str_mv | AT tariqnaladily immunohistochemicalexpressionpatternsofcd45rop105p50jak3toxandil17inearlystagemycosisfungoides AT tasnimabushunar immunohistochemicalexpressionpatternsofcd45rop105p50jak3toxandil17inearlystagemycosisfungoides AT ahmadalhesa immunohistochemicalexpressionpatternsofcd45rop105p50jak3toxandil17inearlystagemycosisfungoides AT raneenalrawi immunohistochemicalexpressionpatternsofcd45rop105p50jak3toxandil17inearlystagemycosisfungoides AT nooralmaani immunohistochemicalexpressionpatternsofcd45rop105p50jak3toxandil17inearlystagemycosisfungoides AT maramabdaljaleel immunohistochemicalexpressionpatternsofcd45rop105p50jak3toxandil17inearlystagemycosisfungoides |